NR4A1 and breast cancer: The burden of these unaddressed symptoms on BC survivors is further underscored by (1) the long duration of treatment (minimum 5 years) and (2) the high prevalence (roughly 75%) of hormone receptor-positive BC65 and it should not be underestimated.